Quarterly ResultAug 7, 2026, 07:09 AM
Treace Medical Q2 Revenue $45.4M, Net Loss $(15.9)M; Raises 2026 Guidance
AI Summary
Treace Medical Concepts, Inc. reported Q2 2026 revenue of $45.4 million, a 4% decrease year-over-year, and a net loss of $(15.9) million, an improvement from the prior year. The company also reported an improved Adjusted EBITDA of $(3.5) million and a 57% reduction in year-to-date cash usage. Following these results, Treace Medical raised its full-year 2026 revenue guidance to a range of $204 million to $212 million and updated its Adjusted EBITDA loss guidance to $3.0 million to $5.0 million. Operational highlights include the limited market release of SuperBite™ and increased adoption of its expanded bunion portfolio.
Key Highlights
- Q2 2026 revenue was $45.4 million, a 4% decrease from $47.4 million in Q2 2025.
- Reported Q2 2026 net loss of $(15.9) million, or $(0.24) per share.
- Adjusted EBITDA for Q2 2026 was $(3.5) million, an improvement from $(3.6) million YoY.
- Year-to-date cash usage reduced by 57% or $3.6 million compared to 2025.
- Cash, cash equivalents, and marketable securities totaled $45.6 million as of June 30, 2026.
- Full-year 2026 revenue guidance raised to $204 million to $212 million.
- Full-year 2026 Adjusted EBITDA loss guidance updated to $3.0 million to $5.0 million.
- 40% of Lapiplasty® surgeon users now incorporate one or more new bunion systems.
Price Impact
More from TMCI